{
    "clinical_study": {
        "@rank": "119491", 
        "acronym": "Intracor", 
        "arm_group": [
            {
                "arm_group_label": "Intracoronary abciximab (Reopro)", 
                "arm_group_type": "Experimental", 
                "description": "Intracoronary abciximab (Reopro)"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intracoronary Reopro"
            }
        ], 
        "brief_summary": {
            "textblock": "Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients\n      suffering an acute myocardial infarction.\n\n      The investigators hypothesise that treatment with intracoronary abciximab, a potent anti\n      platelet agent, at the time of coronary stent insertion, will improve microvascular\n      function."
        }, 
        "brief_title": "A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myocardial Infarction", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "The index of microcirculatory resistance (IMR), an invasive measure of coronary\n      microvascular function, correlates with clinical outcomes in patients with stable angina and\n      ST elevation myocardial infarction. The glycoprotein IIb/IIIa receptor inhibitor, abciximab,\n      improves coronary microvascular function and reduces major cardiac adverse events in\n      patients with acute coronary syndromes. This study will investigate whether an intracoronary\n      bolus of abciximab in patients with non-ST elevation myocardial infarction decreases IMR and\n      improves microvascular function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with acute coronary syndromes\n\n        Exclusion Criteria:\n\n          -  Patient with untreated malignancy, disseminated malignancy, active inflammatory\n             diseases, active infectious diseases patients unable to give informed consent\n             Patients with STEMI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105870", 
            "org_study_id": "SVH 001"
        }, 
        "intervention": {
            "arm_group_label": "Intracoronary abciximab (Reopro)", 
            "description": "This drug will be administered intracoronary before percutaneous coronary intervention.", 
            "intervention_name": "Abciximab", 
            "intervention_type": "Drug", 
            "other_name": "Reopro"
        }, 
        "intervention_browse": {
            "mesh_term": "Abciximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fitzroy", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3101"
                }, 
                "name": "St Vincent's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function", 
        "overall_official": {
            "affiliation": "University of Melbourne", 
            "last_name": "Andrew Wilson, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will assess IMR in the catheterisation laboratory immediately before PCI, then intracoronary reopro or placebo will be administered and we will re-assess IMR 15 minutes post delivery of the study drug. Finally we will perform PCI and immediately measure IMR post-procedure.", 
            "measure": "Index of Microvascular Resistance", 
            "safety_issue": "No", 
            "time_frame": "within 3 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105870"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Melbourne", 
            "investigator_full_name": "A/P Andrew Wilson", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "We will assess for periprocedural myocardial infarction 8 to 24 hours post PCI", 
            "measure": "Incidence of periprocedural myocardial infarction", 
            "safety_issue": "Yes", 
            "time_frame": "within 24 hours"
        }, 
        "source": "University of Melbourne", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Melbourne", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}